Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck
Alec Kacew(Hospital of the University of Pennsylvania), Glenn J. Hanna(Dana-Farber Cancer Institute), Jason Kass(Brigham and Women's Hospital), Ethan Harris(University of Chicago), Roy B. Tishler(Dana-Farber Cancer Institute), Danielle N. Margalit(Harvard University), Jochen H. Lorch(Northwestern University), Robert I. Haddad(Georgetown University), Jonathan D. Schoenfeld(Brigham and Women's Hospital)
Cited by 30
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926